Lazucirnon

DB15269InvestigationalSmall molecule

ALK-4290 is under investigation in clinical trial NCT03558061 (Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration).

Formula / weight: C₂₇H₃₄ClN₅O₃ · 512.05 g/mol (avg)
Code names: ALK-4290

Resolves to

Compound

UNIIR0T9LLR4TNCAS1251528-23-0ChEMBLCHEMBL3670800

Structure

InChIKeyDWKNOLCXIFYNFV-HSZRJFAPSA-NSMILESCN(C)C(=O)C1=CC(NC(=O)[C@H]2CCC(=O)N2C2CCN(CC3=CC=C(Cl)C(C)=C3)CC2)=NC(C)=C1

Targets

P51677CCR3

What you can answer from here — as of October 27, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Lazucirnon, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account